Spike Protein Targeting Shows Promise in Immune Response Detection

The SARS-CoV-2 virus outbreak is a global pandemic, with millions of individuals around the world affected and communities worldwide disrupted. Understanding how the adaptive immune response works in SARS-CoV-2 infection could be one step forward on the path to developing vaccines.

In the study, “Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals,” researchers tested sera from COVID-19 patients who had recently become virus-free and were discharged from the hospital. Researchers detected SARS-CoV-2-specific humoral and cellular immune response – specifically they saw antibodies specific to the receptor-binding domain of the coronavirus spike protein (S-RBD) and found a correlation between neutralizing antibody titers and anti-S-RBD IgG. Researchers observed no such correlation with anti-nucleocapsid protein IgG. Researchers concluded that, “Anti-S-RBD IgG might be useful in analyzing serum neutralization capabilities in COVID-19 patients.”1

Furthermore, researchers noted that S-RBD seemed to induce broader immune cell responses. This observation suggests that S-RBD may be a promising target for SARS-CoV-2 vaccines, which could help individuals build humoral immunity or cellular immunity to this potentially deadly disease.

Spike Protein

Peer-Reviewed Clinical Study Detection of SARS-CoV-2-specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

In this study of post-hospital discharge COVID-19 patients, researchers discovered SARS-CoV-2-specific humoral immunity and cellular immunity through the detection of antibodies specific to the receptor-binding domain of the coronavirus spike protein (S-RBD).

Complete the form below to download your copy of the peer-reviewed clinical study.

Webinar Clinical Value of Spike Protein Antibodies in Serology Testing

The Beckman Coulter Access IgG assay targets the Receptor Binding Domain (RBD) of the Spike (S) protein. Find out more about the clinical value of the Spike Protein Antibody in this comprehensive, interactive data overview.

Watch webinar

You may also be interested in:

Access SARS-CoV-2 IgG Antibody Test 
Laboratory studies show that to identify an immune response against the SARS-CoV-2 coronavirus, it is important to target the right antibodies. The Access SARS-CoV-2 IgG assay detects antibodies to the receptor-binding domain of the coronavirus spike protein, which may be important for assessing humoral and cellular immunity, based on laboratory studies. Learn more about this assay, which is available for Access 2, DxI 600 and DxI 800 immunoassay analyzers

Resources to Help in Navigating the SARS-CoV-2 Virus Pandemic 
The SARS-CoV-2 virus and the COVID-19 disease have disrupted the everyday lives of men, women and children around the world. Watch videos and access curated resources developed to help you in understanding, and managing, the SARS-CoV-2 virus pandemic. 

Article to appear in Immunity

1Ni, L., Ye, F., Cheng, M.-L., Feng, Y., Deng, Y.-Q., Zhao, H., … Dong, C. (2020). Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity. https://doi.org/10.1016/j.immuni.2020.04.023